The recent and rapid spread of the novel coronavirus, SARS-CoV-2, has called for the development of new assays to detect the presence of this virus in patient samples or evidence of recent infection. At Bethyl, our strategy has been to develop a high-quality assay to detect the presence of anti-SARS-CoV-2 antibodies in patient sera to accelerate discovery that improves lives. Let’s work together.
The enzyme linked immunosorbent assays (ELISA) are for the detection of Human IgG or IgM antibodies specific for SARS-CoV-2 virus, specifically the RBD protein, in serum or plasma. These kits contain sufficient components to detect these antibodies in up to 45 samples, if tested in duplicate. It is intended to aid in identifying individuals with an adaptive immune response to SARS-CoV-2, indicating recent or prior infection.
Our kit provides for an indirect ELISA, in which a recombinant receptor binding domain (RBD) of the Spike1 protein of SARS-CoV-2, where this protein has been hypothesized as one of the most immunogenic of its proteins, making it a good candidate for detecting immune response.
Our commitment to excellence as we maintain a high standard of quality products, customer care, and technical support.
Our scientific team ensures that every antibody sold by us has been manufactured and validated to exacting standards at our sole US location
Using an ELISA to detect SARS-CoV-2 antibodies is typically considered a more efficient choice than a lateral flow immunoassay, which is commonly used for clinical diagnostics due to the speed at which they can be performed. ELISA is also the more sensitive of the two assays. A complete procedure overview is available by viewing the protocol.
We are a leading, trusted partner across labs globally for bulk anti-Human IgG, IgM & IgA antibodies to support COVID-19 (SARS-CoV-2) seroconversion assay development.
